We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 129% below its sector, cheaper than its peers on earnings.
Ortin Global Ltd., established in 1986 and headquartered in Hyderabad, India, is an Indian enterprise specializing in the manufacturing and trading of pharmaceuticals, drugs, and their intermediates. The company, formerly known as Ortin Laboratories Limited until its name change in June 2024, offers an extensive portfolio of pharmaceutical formulations available as tablets, capsules, syrups, and dry powders. These products address a wide spectrum of therapeutic areas, including anti-diabetics, anti-allergics, cardiovascular conditions, sedatives, anti-helminthics, analgesics, antipyretics, various antibiotics (quinolones, penicillins, cephalosporins, macrolides), antifungals, chemotherapeutics, antacids, anti-ulcerants, anti-spasmodics, calcium and iron supplements, anti-arthritic drugs, protein supplements, enzymes, vitamins, as well as psychiatry, appetite stimulant, gynecological, and anti-retroviral medications. Beyond finished dosage forms, Ortin Global produces active pharmaceutical ingredient (API) intermediates for anti-retroviral, anti-diabetic, analgesic, antipyretic, antibiotic, antifungal, anti-ulcerant, and anti-malarial applications. Its manufacturing capabilities also extend to fine chemicals, Grignard products, and alkali metal compounds. The company provides a range of specialized services, including process development, characterization of processes and products, analytical research and development, and assay development. It also offers R&D for new formulation brands and diagnostic services, focusing on the creation of rapid flow kits, assays, and reagents. Additionally, Ortin Global secures long-term contracts for manufacturing intermediates and developing new APIs, functions as a merchant exporter of finished pharmaceutical formulations, and holds interests in real estate.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save ORTINGLOBE.NS and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
